Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma.
dc.contributor.author | Dreyling, M | |
dc.contributor.author | Morschhauser, F | |
dc.contributor.author | Bouabdallah, K | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Bron, D | |
dc.contributor.author | Linton, Kim M | |
dc.contributor.author | Assouline, S | |
dc.contributor.author | Verhoef, G | |
dc.contributor.author | Thieblemont, C | |
dc.contributor.author | Vitolo, U | |
dc.contributor.author | Garcia-Vargas, J | |
dc.contributor.author | Gorbatchevsky, I | |
dc.contributor.author | Neves, M | |
dc.contributor.author | Grunert, J | |
dc.contributor.author | Hiemeyer, F | |
dc.contributor.author | Childs, B | |
dc.contributor.author | Zinzani, P | |
dc.date.accessioned | 2016-12-16T16:21:25Z | |
dc.date.available | 2016-12-16T16:21:25Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma. 2016, 39: 310-310 Oncol Res Treat | en |
dc.identifier.uri | http://hdl.handle.net/10541/620062 | |
dc.language.iso | en | en |
dc.title | Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma. | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Universitatsklinik Grosshadern/LMU, Medizinische Klinik 111, Munchen | en |
dc.identifier.journal | Oncology Research and Treatment | en |
dc.description.collection | Lymphoma Research Team | en |